← Back to Search

Amino Acid Mixture

Enterade for Multiple Myeloma

N/A

Waitlist Available

Led By Brett Glotzbecker, MD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 45 days

Awards & highlights

Study Summary

This trial will compare the safety and effectiveness of Enterade to a placebo in participants who are undergoing stem cell transplant.

Eligible Conditions

Multiple Myeloma
Non-Hodgkin's Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 45 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 45 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 45 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of Participants With Grade 3 or Higher Diarrhea GI Toxicity

Secondary outcome measures

Calorie Consumption

Duration Of Hospitalization (Days) From Admission To Discharge

Maximum Daily Stool Frequency

+5 more

Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: Enterade and Standard Supportive CareExperimental Treatment2 Interventions

Two 8 oz. bottles of Enterade will be administered daily Enterade will be given orally from admission until day +14 or until discharge Standard Supportive Care will be administered according to institution's practice

Group II: Placebo and Standard Supportive CarePlacebo Group2 Interventions

Two 8 oz. bottles of Placebo will be administered daily Placebo will be given orally from admission until day +14 or until discharge Standard Supportive Care will be administered according to institution's practice

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Enterade

2022

N/A

~140

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor

1,078 Previous Clinical Trials

340,758 Total Patients Enrolled

51 Trials studying Multiple Myeloma

34,208 Patients Enrolled for Multiple Myeloma

Entrinsic HealthUNKNOWN

Brett Glotzbecker, MDPrincipal InvestigatorDana-Farber Cancer Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any opportunities currently available for individuals to enroll in this experiment?

"Allegations from clinicaltrials.gov reveal that this medical trial is no longer accepting participants, as the most recent update was on May 1st 2019 and it was initially posted in October 2016. Despite not being able to join this study, an abundance of other alternatives are currently recruiting volunteers."

Answered by AI

What regulatory bodies have certified Enterade as safe and efficacious?

"Enterade's safety has been substantiated to a degree, so it received an evaluation of 2 on our scale. However, efficacy data is still lacking at this stage in the clinical trial process."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma

Mahasweta Gooptu 2016. "A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02919670.